LABORATORY RESEARCH DOT1L Cooperates with the C-Myc-p300 Complex to Epigenetically Derepress CDH1 Transcription Factors in Breast Cancer Progression The authors identified that DOT1L cooperates with c-Myc and p300 acetyltransferase to epigenetically activate epithelial–mesenchymal transition regulators in breast cancer progression. [Nat Commun] Full Article KLF5 Promotes Breast Cancer Proliferation, Migration and Invasion in Part by Upregulating the Transcription of TNFAIP2 Investigators demonstrated that TNFAIP2, a tumor necrosis factor-α-induced gene, is a direct Kruppel-like factor 5 (KLF5) target gene. The expression of TNFAIP2 is highly correlated with the expression of KLF5 in breast cancers. [Oncogene] Abstract LMTK3 Represses Tumor Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer Researchers identified KRAB-associated protein 1 (KAP1) as a binding partner of LMTK3. The LMTK3/KAP1 interaction is stabilized by PP1α, which suppresses KAP1 phosphorylation specifically at LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in transcriptional repression of LMTK3-bound tumor suppressor-like genes. [Cell Rep] Full Article | Graphical Abstract | Press Release Blockade of Wnt/β-Catenin Signaling Suppresses Breast Cancer Metastasis by Inhibiting CSC-Like Phenotype Researchers investigated the effects of inhibiting Wnt/β-catenin signaling on cancer cell migratory potential by examining the expression of cancer stem cell (CSC)-related genes, and they examined how this pathway links metastatic potential with tumor formation in vitro and in vivo. [Sci Rep] Full Article Rap2B Promotes Proliferation, Migration, and Invasion of Human Breast Cancer through Calcium-Related ERK1/2 Signaling Pathway Rap2B knockdown inhibits cell proliferation, migration, and invasion abilities via calcium related-ERK1/2 signaling. In addition, overexpression of Rap2B promotes cell proliferation, migration and invasion abilities, which could be neutralized by BAPTM/AM and U0126. [Sci Rep] Full Article miR-205-5p-Mediated Downregulation of ErbB/HER Receptors in Breast Cancer Stem Cells Results in Targeted Therapy Resistance Researchers report that miR-205-5p is highly expressed in breast cancer stem cells and represses directly ERBB2 and indirectly EGFR leading to resistance to targeted therapy. [Cell Death Dis] Full Article Mimicking Postmenopausal Steroid Metabolism in Breast Cancer Cell Culture: Differences in Response to DHEA or Other Steroids as Hormone Sources. Investigators presented a comparative study of steroid-converting enzymes with the provision of dehydroepiandrosterone (DHEA) and the direct substrates, estrone or dihydrotestosterone, or additional steroids as hormone sources, in breast cancer cells. [J Steroid Biochem Mol Biol] Abstract Regulation of Stem Cells-Related Signaling Pathways in Response to Doxorubicin Treatment in Hs578T Triple-Negative Breast Cancer Cells The authors investigated the cellular and molecular signaling of two claudin-low triple-negative breast cancer cells to doxorubicin and docetaxel treatment. While the treatment reduced the proliferation, aggregation and mammosphere forming ability of stem-like cells derived from Hs578T cell line, stem-like cells derived from MDA-MB-231 cells were not significantly affected. [Mol Cell Biochem] Abstract Local Variations of HER2 Dimerization in Breast Cancer Cells Discovered by Correlative Fluorescence and Liquid Electron Microscopy The authors studied the intra- and intercellular variation of HER2 at the single-molecule level in intact SKBR3 breast cancer cells. [Science Advances] Abstract | Press Release CLINICAL RESEARCH A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies Scientists assessed dose-limiting toxicities and maximum-tolerated dose for the combination of oral ridaforolimus plus oral MK-2206 in patients with advanced solid tumors. Efficacy was evaluated in patients with biomarker-identified estrogen receptor-positive breast cancer or castration-resistant prostate cancer with PI3K pathway addiction. [Clin Cancer Res] Abstract Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial Investigators determined the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2/neu)-negative metastic breast cancer. [PLoS One] Full Article |